Pegdinetanib
Pegdinetanib
Pegdinetanib (pronunciation: peg-din-e-tan-ib) is a novel biopharmaceutical drug currently under investigation for its potential use in the treatment of various types of cancer.
Etymology
The name "Pegdinetanib" is derived from the drug's chemical structure and its intended therapeutic use. "Peg" refers to Pegylation, a process that involves the attachment of polyethylene glycol (PEG) to a molecule, in this case, a drug. "Dinetanib" is a combination of syllables often used in the nomenclature of tyrosine kinase inhibitors, a class of drugs that Pegdinetanib belongs to.
Mechanism of Action
Pegdinetanib is a tyrosine kinase inhibitor that works by blocking the action of certain proteins that signal cancer cells to grow and divide. By inhibiting these proteins, the drug can slow down or stop the growth of cancer cells.
Related Terms
- Biopharmaceutical: A type of drug produced using biotechnology.
- Cancer: A group of diseases characterized by the uncontrolled growth and spread of abnormal cells.
- Pegylation: A process that involves the attachment of polyethylene glycol (PEG) to a molecule.
- Tyrosine kinase inhibitors: A class of drugs that block the action of tyrosine kinases, proteins that can stimulate cancer growth.
See Also
External links
- Medical encyclopedia article on Pegdinetanib
- Wikipedia's article - Pegdinetanib
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski